Hydrafil™
HYDRAFIL™, is a proprietary hydrogel technology that when heated becomes a liquid that can be injected through a 17-gauge needle into the nucleus of an intervertebral disc. Once it enters the body the gel incorporates with the existing nucleus and cools to form an integrated solid. This implant mimics the biomechanical properties of the natural disc and preserves spinal motion.
The burden of low back pain in the United States is immense.
52 Million
291 Million
$50 Billion
Latest News
Latest news on ReGelTec and HYDRAFIL to treat degenerative disc disease.
HYDRAFIL® Presentation Receives Top Abstract Award at the 6th Annual American Society of Pain and Neuroscience Annual Meeting
ReGelTec, Inc., announced that Dr. Douglas Beall received the “Top Abstract Award” from the American Society of Pain and Neuroscience (ASPN) for his presentation of the 3-Year follow-up data on chronic low back pain patients treated with ReGelTec’s HYDRAFIL System.
ReGelTec’s Hydrafil Injectable Hydrogel Studied to Treat Low Back Pain Caused by Degenerative Disc Disease
According to the Society of Interventional Radiology (SIR), a small study showed an experimental formulation of a hydrogel injected into spinal discs was safe and effective in substantially relieving chronic low back pain caused by degenerative disc disease (DDD).
The FDA Approves IDE for ReGelTec’s Pivotal Study of HYDRAFIL® for Chronic Low Back Pain due to Degenerative Disc Disease
ReGelTec, Inc., announced that the U.S. Food and Drug Administration has approved an IDE for the company’s pivotal study to support premarket approval of its HYDRAFIL® System.